Castor Connect 对比 Curebase 的使用情况和统计数据

Castor Connect enables study participants to complete Castor Surveys (ePRO questionnaires) via a native mobile application. - Compliant, secure, user-friendly ePRO solution - Configured using our EDC product to be as simple or complex as your study demands - Flexible and secure, offline data storage with manual sync and native security mean participants can submit their study data whenever they need An invitation to take part or the scanning of a participant-specific activation code is required to use this application. You can find more information about Castor surveys or Castor Connect at castoredc.com/epro
  • Apple 应用商店
  • 免费
  • 健康与健身

商店排名

- -

The Curebase application provides trial participants with a single platform to view and complete all remote study activities including: - Signing study documents - Uploading medical records - Scheduling appointments - Meeting with telehealth providers - Completing questionnaires - Receiving study compensation …and more! Step 1: Download the Curebase app Step 2: Log into your Curebase account Step 3: Track and manage your study participation Note: this application is only for patients who are currently enrolled in a Curebase study and directed to download this application. About Curebase At Curebase, our mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians everywhere to enroll patients in the communities where they live. By applying cutting-edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up.
  • Apple 应用商店
  • 免费
  • 医疗

商店排名

- -

Castor Connect与Curebase排名比较

对比 Castor Connect 与 Curebase 在过去 28 天内的排名趋势

排名

没有可用的数据

Castor Connect 对比 Curebase 的排名,按国家/地区比较

对比 Castor Connect 与 Curebase 在过去 28 天内的排名趋势

无数据可显示

通过免费试用版比较任何网站

开始使用
Castor Connect VS.
Curebase

十二月 17, 2024